Business Wire

NY-BCW

Share
Burson-Marsteller Founder Harold Burson Passes Away at Age 98

Harold Burson, once a 14-cents-per-column-inch stringer for a Memphis newspaper, who reported the Nuremberg Trial for the Army radio network in Europe and whose one-man consultancy became by 1983 the world’s largest public relations firm, died on January 10, 2020. He was 98.

Burson played a leading role in transforming the practice of public relations from a cottage industry to a global business that engaged thousands of employees. He stepped down as Chief Executive Officer of Burson-Marsteller in 1988 but continued in an active capacity for more than a quarter century and came to work nearly every day well into his 90s.

In 1999, a survey by PRWeek, a leading public relations industry trade publication, named Burson as “the century’s most influential PR figure.” This recognition reflected his role as counselor to and confidant of corporate chief executive officers, government leaders and heads of public sector institutions.

His PRWeek citation read:

“The architect of the largest public relations agency in the world today (1999), Burson-Marsteller Chairman Harold Burson’s contribution is immense in many other ways besides. He started practicing the concept of integrated marketing decades before the term was even invented. He brought PR into the advertising business at Young & Rubicam as an equal (it’s arguably never been achieved again). His development of training programs set the benchmark that other agencies have only recently caught up with. He has personally sponsored and supported programs, industry bodies, universities and charities to improve the profession. His mentoring of talent has spawned a whole wave of ex-Burson PR agency start-ups. He created a unique Burson culture that still unites former employees. And, last but not least, his personal counsel has enlightened the thinking of boardrooms at many Fortune 100 companies and across the globe.”

He was a strong proponent of the corporation’s role in society as a social entity, insisting that the mission of a corporation was to deliver a good product at a fair price, treat its employees fairly in terms of compensation and retirement, deal fairly with suppliers, support essential community activities in areas where it operated, and reward its stockholders with a fair return on their investment. But he warned that the principal objective of the corporation was to make a profit that enabled it to fund its responsibilities as a social entity.

Born February 15, 1921, in Memphis, Tennessee, the son of emigrants from Leeds, Yorkshire, England, he started school in the third grade and graduated from high school at age 15. He enrolled at the University of Mississippi (Ole Miss) knowing that his campus correspondent stringer job for the Memphis Commercial Appeal would cover his college tuition and expenses. Six months after graduation, he accepted a public relations position at a large engineering and architectural firm when, as he said, “they doubled my salary from $25 to $50 per week and gave me the use of a car.”

Burson enlisted in the United States Army in 1943 and became part of an engineer combat group in Europe. In 1945, he was transferred to the news staff of the American Forces Network a month before the war ended in Europe.

Later in 1945, he was assigned to report on the Nuremberg Trial and was the only reporter to obtain an interview during the trial with Associate Justice Robert H. Jackson, the chief American prosecutor. Although Justice Jackson had vowed not to grant interviews, Burson argued that his audience, the American GIs who fought the war, were entitled to hear firsthand from the chief American prosecutor. Only 24-years-old when the Nuremberg Trial began, Burson was believed to have been the last living reporter who covered the historic trial.

Following his discharge from the Army in 1946, Burson opened a public relations firm in New York in “a tiny nook in a client’s office” next to the desk of a part-time executive assistant. Never having heard the word “differentiation” used in a competitive sense, he described his firm as specializing in business-to-business clients. The firm he worked for before his Army service was in that category and he quickly learned that few business-to-business companies employed public relations consultants.

In 1952, Burson’s firm had a staff of five when a friend at The New York Times, responding to a query from the owner of a Chicago advertising agency, recommended Burson for a Pittsburgh-based project. Through this opportunity, he came to meet William A. (Bill) Marsteller, with whom his name was linked by a hyphen for 65 years. The Burson firm was hired for the project – to publicize the purchase by Rockwell Manufacturing Company of the first helicopter to be used for executive travel. Rockwell subsequently became a full-fledged client.

Shortly thereafter, Marsteller introduced Burson to the chief executive officer of another client, Clark Equipment Company, which led to still more business. The affiliation with Marsteller worked so well that Burson proposed establishing a new company jointly owned by the two parties. It took the name Burson-Marsteller and opened March 2, 1953 with offices in New York and Chicago and offered “integrated communications services” to business-to-business clients, believed to be the first to do so.

In speeches and articles, Burson has cited two “defining moments” that accounted for the company’s rapid growth. The first was the creation of the European Common Market in the late 1950s. Burson’s firm was the second to establish an office in Europe – in Geneva, Switzerland in early 1961 – and announced its intention to become a global operation over the next quarter century. Though still a speck on the public relations spectrum in the U.S., Burson-Marsteller became known as “the other international public relations firm.” During the 1960s, its annual revenues surged tenfold, from $410,000 to $4.4 million.

The firm’s second defining moment was its selection in 1970 by General Motors (GM) to be its sole public relations counsel, a response to allegations that GM hired private investigators to follow the self-appointed public watchdog, Ralph Nader, after his scathing book questioning the safety of GM’s highly touted Chevrolet Corvair. After GM’s CEO was called to testify before a Congressional committee, the company, on instructions from its board of directors, hired an outside public relations firm to consult with management. Competing against the two largest U.S. firms, Burson-Marsteller was chosen for the assignment, which continued for more than a decade.

During the 1970s, the firm’s revenues increased from $5.2 million to $28.3 million. It added about a dozen new offices in Europe, including London, Paris, Brussels and Frankfurt, and in Asia, in Hong Kong, Tokyo and Singapore. Its clients included both American multinationals and local businesses.

In 1979, Burson engineered the merger of Burson-Marsteller and Marsteller Advertising with the global advertising giant Young & Rubicam, becoming a member of its seven-person executive committee. At the time of the merger, Burson-Marsteller had revenues of $28.3 million and 16 offices. Four years later, when Burson-Marsteller became the world’s largest public relations firm, it had revenues of $63.8 million and 30 offices, including branches in Latin America, Australia and the Middle East.

One of the firm’s specialties was crisis management, ranging from the major Tylenol recalls in 1982 and 1985, which were often referred to as models for corporate management in times of crisis, to the celebrated introduction of “New Coke” and the reintroduction of Coca-Cola Classic in 1985, an undertaking in which Burson himself was a prime participant. After the “New Coke” debacle and the re-introduction of Coca-Cola Classic, he summarized the exercise as “[w]e got a hole-in-one after the ball hit the tree.” The firm also represented Union Carbide in the aftermath of the discharge of toxic chemicals at its plant in Bhopal, India; Pan Am Airways after the Lockerbie (Scotland) crash; and Dow Corning following the U.S. Food and Drug Administration’s decision to ban silicone breast implants. Burson-Marsteller also had a long-time active role in representing the Olympic Games and its corporate sponsors.

Burson received numerous awards from public relations organizations including Hall of Fame designations by the Public Relations Society of America, the Arthur W. Page Society, PRWeek, PR News, the Institute of Public Relations, the Alan Campbell Johnson Award (England), as well as numerous citations by colleges and universities in the United States, Europe and China. He was awarded an honorary degree by Boston University in 1988, and a chair in public relations was established in his name in 1995. He is also in the Hall of Fame at his alma mater, Ole Miss, and shares a place in the Humes High School Hall of Fame in Memphis with Elvis Presley.

He was active in numerous public service organizations, principally the John F. Kennedy Center for the Performing Arts. As a board member of Kennedy Center Productions, he negotiated Japan’s $3 million bicentennial gift in 1976 to construct the Terrace Theater. He also was instrumental in establishing the Kennedy Center Corporate Fund in 1977.

Another of his interests was economic education. He was chairman of the Council on Economic Education in the early 1990s and was an active member of the Economic Club of New York since 1979, including serving as chairman of the organization’s centennial dinner in 2007. In conjunction with the dinner, he proposed the creation of a Centennial Society composed of members who contribute at least $10,000 to the establishment of a club endowment fund.

He was a Presidential appointee to the Commission of Fine Arts in Washington and was a member during the deliberations that led to building the Vietnam War Memorial and the redevelopment of Pennsylvania Avenue in the 1980s. He also chaired the Public Relations Advisory Committee of the U.S. Information Agency during the second Reagan administration and under President George H.W. Bush.

In more recent years, he was a member of the board of trustees of the Museum of the American Revolution, which is the first museum that relates the entire history of the American Revolution. He was also a member of the Eisenhower Memorial Commission’s Advisory Committee.

Although never engaged in partisan politics, he served as public relations advisor to President Ronald Reagan after he left the White House. He did so on the basis that his services were offered pro bono.

In 2017, at the age of 96, he published his memoir, THE BUSINESS OF PERSUASION: Harold Burson on Public Relations (RosettaBooks).

Burson was married to Bette Foster Burson for one month short of 63 years. He is survived by two sons, Scott F. Burson (Wendy Liebow Burson) of Lexington, Massachusetts and Mark Burson (Ellen Jones Burson) of Westlake Village, Calif., and five grandchildren: Allison Burson, Esther Burson, Wynn F. Burson (Steven Cateron), Holly Burson and Kelly Burson.

Donations may be made to the Boston University College of Communication.

About BCW

BCW (Burson Cohn & Wolfe), one of the world’s largest full-service global communications agencies, is in the business of moving people on behalf of clients. Founded by the merger of Burson-Marsteller and Cohn & Wolfe, BCW delivers digitally and data-driven creative content and integrated communications programs grounded in earned media and scaled across all channels for clients in the B2B, consumer, corporate, crisis management, CSR, healthcare, public affairs and technology sectors. BCW is a part of WPP (NYSE: WPP), a creative transformation company. For more information, visit www.bcw-global.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye